You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page
No matches

59 search results for: mechanism of disease

Can advanced systemic therapies modify patho<b>mechanism</b>s in AD?
expert video

Can advanced systemic therapies modify pathomechanisms in AD?

Dermatology
Dr. Ramien discusses evidence showing that advanced therapies can modify the mechanisms of atopic dermatitis, improving skin barrier function, normalizing the skin microbiome, and reducing chronic itch.
View more
Emerging Understanding <b>of</b> Chronic Itchy Skin <b>Disease</b>s – Shared and Unique Drivers in AD, PN, and CSU
Infographic

Emerging Understanding of Chronic Itchy Skin Diseases – Shared and Unique Drivers in AD, PN, and CSU

Dermatology
An infographic summarizing the shared and distinct features of AD, PN, and CSU that are driven by type 2 inflammation.
View more
What role does IL-4 and IL-13 have in driving Type 2 inflammatory skin <b>disease</b> (AD, PN, CSU)?
expert video

What role does IL-4 and IL-13 have in driving Type 2 inflammatory skin disease (AD, PN, CSU)?

Dermatology
Dr. Oscar Palomares explains that IL-4 and IL-13 are crucial cytokines in type 2 inflammation, playing both unique and overlapping roles, including T cell expansion and contributing to clinical symptoms in chronic diseases.
View more
ERS 2024 | Pathophysiologic <b>Mechanism</b>s <b>of</b> Airway Remodeling in Severe Asthma
expert video

ERS 2024 | Pathophysiologic Mechanisms of Airway Remodeling in Severe Asthma

Pulmonology
Professor Celeste Porsbjerg presents the pathophysiology and disease processes involved in airway remodeling in severe asthma.
View more
Connecting the Dots from Type 2 Inflammation to Patient Perspectives
expert video

Connecting the Dots from Type 2 Inflammation to Patient Perspectives

Type 2 Inflammation
Learn the connection between chronic type 2 inflammation, symptoms, and impact on quality of life in diseases with underlying type 2 inflammation
View more
ERS 2024 | Living With COPD: Linking Inflammation with Patient Burden
expert video

ERS 2024 | Living With COPD: Linking Inflammation with Patient Burden

Pulmonology
Professor Henrik Watz explores the complex relationship between inflammation and COPD, highlighting its impact on patients' health and overall quality of life.
View more
The Role <b>of</b> Type 2 Inflammation in Atopic Dermatitis
expert video

The Role of Type 2 Inflammation in Atopic Dermatitis

Dermatology
The impact of type 2 inflammation and barrier dysfunction in the pathogenesis of chronic disease in atopic dermatitis.
View more
Under the Itchy Surface: The Insidious, Cumulative Burden <b>of</b> Type 2 Inflammation in AD
expert video

Under the Itchy Surface: The Insidious, Cumulative Burden of Type 2 Inflammation in AD

Dermatology
In this video from the March 2025 ADVENT symposium in Orlando, Florida, Dr. Eric Simpson discusses the systemic nature of atopic dermatitis (AD) and how the disease burden extends beyond the skin. Through the lens of cumulative life course impairment, Dr. Simpson goes on to explore how persistent type 2 inflammation in AD may drive both atopic and nonatopic comorbidities, emphasizing the potential importance of early and effective therapeutic intervention to alter disease progression
View more
Role <b>of</b> Type 2 Inflammation in Skin Barrier Dysfunction in AD
expert video

Role of Type 2 Inflammation in Skin Barrier Dysfunction in AD

Type 2 Inflammation
Dr. Robert Bissonnette explains the role of type 2 inflammation in skin barrier dysfunction and how regulation of type 2 inflammation can normalize the skin barrier and potentially modify the disease with early intervention.
View more
Understanding IL-33: A Key Factor in COPD Pathogenesis
interactivity

Understanding IL-33: A Key Factor in COPD Pathogenesis

Pulmonology
Explore the role of IL-33 in COPD pathophysiology and its potential as a therapeutic target
View more
Unique Characteristics <b>of</b> Itch in AD, PN, and CSU – A Panel Discussion
expert video

Unique Characteristics of Itch in AD, PN, and CSU – A Panel Discussion

Dermatology
Dr. Kim and Dr. Elmariah discuss how unique characteristics of itch in AD, PN, and CSU impact patients.
View more
Itch: The Common Thread in Dermatological Type 2 Inflammation (AD, PN, and CSU)​ - Panel Discussion
expert video

Itch: The Common Thread in Dermatological Type 2 Inflammation (AD, PN, and CSU)​ - Panel Discussion

Dermatology
Panel discussion exploring how itch differs across AD, PN, and CSU, and how it affects pediatric patients with AD.
View more

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 v3.0 11/2023

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: AlgeriaChange country/region